The US Food and Drug Administration (FDA) has approved Johnson & Johnson Vision’s (J&J) ACUVUE Abiliti Overnight Therapeutic Lenses for managing myopia.
J&J noted that these lenses are the first orthokeratology (ortho-k) contact lens to receive FDA approval in this indication. According to clinical studies, ortho-k lenses were a safe and efficient option for myopia management.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Tailored to match a patient’s eye depending on its corneal shape, Abiliti Overnight ortho-k contact lenses can reshape the cornea temporarily.
To be available by the end of the year in the US, the contact lens will come in two designs, Abiliti Overnight Therapeutic Lenses and Abiliti Overnight Therapeutic Lenses for Astigmatism.
J&J research and development global head Xiao-Yu Song said: “The FDA approval of Abiliti Overnight marks an important milestone in our commitment to help change the trajectory of eye health and reshape the future of children with myopia.
“We look forward to supporting parents and eye care professionals in their care of children with comprehensive resources, starting with Abiliti Overnight Therapeutic Lenses and continuing with additional products and services to address the progression of myopia.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAbiliti Overnight contact lenses feature corneal topography, refractive error and other measurements linked to a fitting software.
This user-friendly software offers an exact measure of the corneal shape and precisely guides the eye care specialist during the fitting procedure for first fit rates of about 90%.
J&J paid consultant Dr Moshe Mendelson said: “The prevalence of myopia in children is increasing, and as optometrists, we are on the front lines of this epidemic that may threaten the vision of future generations.
“For too long we have relied on increasing the prescription of glasses for children while having few resources to address the underlying disease and help change this worrying trajectory of eye health.”
The company noted that the latest FDA approval for the lens is a result of its partnership with Menicon to develop therapeutic contact lenses for myopia under the ACUVUE Abiliti brand.
